Wegovy in tablet form: what the new oral option actually is

How does semaglutide work when you swallow it rather than inject it?

Most people assume a medicine that works as an injection simply cannot survive the stomach. That is the core misconception here, and it is a reasonable one. The Wegovy tablet gets around this by pairing semaglutide with an absorption enhancer called SNAC (salcaprozate sodium). SNAC temporarily alters the local environment of the stomach lining, allowing semaglutide to pass through into the bloodstream before digestive enzymes break it down.

Once absorbed, it works exactly as the injection does: it activates GLP-1 receptors involved in appetite regulation and slows how quickly the stomach empties. The result is a sustained reduction in hunger across the day. The NHS medicines page for semaglutide describes the mechanism in plain language if you want a reference point.

Because absorption depends on that stomach-lining interaction, timing matters more than it does with an injection. The tablet is taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120 ml). You then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Coffee counts as something else. The specific instructions in the Patient Information Leaflet take precedence over any general summary, including this one.

Who is the Wegovy tablet actually licensed for?

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition. That condition might be high blood pressure, raised cholesterol, prediabetes, obstructive sleep apnoea, or similar. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

There are groups for whom the tablet is not suitable. It is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. Certain conditions, including a personal or family history of medullary thyroid carcinoma, require a careful prescriber discussion before any semaglutide is considered.

A detail worth knowing: the NHS has not yet commissioned the Wegovy tablet. NICE would need to appraise it first. For now, it is available through private prescription only. If you are exploring the full range of weight-loss treatments that require a clinical assessment, the treatments overview at nume sets out what is currently available.

Women taking oral contraceptives should talk to their prescriber about timing and any adjustments needed, particularly during the early escalation phase. This is standard advice for oral medicines that can affect gut absorption.

What did the clinical trial results actually show?

The phase 3 trial supporting the approval was OASIS 4, which ran for 64 weeks and included 307 adults living with obesity or overweight alongside at least one weight-related condition, none of whom had type 2 diabetes. Participants followed lifestyle changes alongside the medicine or a placebo.

The average weight loss across everyone taking the Wegovy oral tablet, regardless of how consistently they stuck to it, was around 13.6%. Among those who adhered fully to treatment throughout, the figure was closer to 16.6%. That distinction matters: the 17% figure sometimes cited refers to the fully-adherent group specifically, not to everyone in the trial.

For context, the injection at 2.4 mg produced around 15% average weight loss over 68 weeks in the STEP 1 trial. The tablet's results are in a similar range, though the trials were not designed as a direct head-to-head comparison. The most commonly reported side effects in OASIS 4 were gastrointestinal: nausea, diarrhoea, and vomiting appeared more often in the semaglutide group than the placebo group. These were generally described as mild to moderate and tended to ease as participants moved through the escalation phase.

For a broader look at how oral and injectable semaglutide compare, the page covering semaglutide in tablet form covers the similarities and practical differences in more detail.

Is Wegovy in tablet form available at a private pharmacy right now?

Yes, as a private prescription medicine. It was approved in June 2026, and private pharmacies are beginning to stock it, though availability can vary. The important distinction is between Wegovy available in pill form and Rybelsus, which is also oral semaglutide but a separate product licensed only for type 2 diabetes at different doses (3 mg, 7 mg, and 14 mg). Those strengths are not part of the weight-loss tablet schedule and should not be confused with it.

On cost: private weight-loss prescriptions vary between providers, and any quoted price from a legitimate service should include the prescription and clinical assessment. If you want to understand what you are paying for, the Wegovy tablets page gives an honest account of what shapes the cost, including what to watch for when comparing prices online. The semaglutide tablet pricing page gives an honest account of what shapes the cost, including what to watch for when comparing prices online.

No refrigeration is needed for the tablet, which makes it easier to store at home and carry when travelling. That practical difference, alongside the injection-free routine, is the reason many people are asking about wegovy in tablet form. Whether it is right for you depends on your health history and what your prescriber finds on assessment. A qualified clinician reviews every consultation at nume before anything is prescribed. To see whether you might be eligible, find out more about how the service works or check your eligibility through a free consultation.